The deal will see the low-profile gene therapy startup merge with floundering Inotek before embarking on a clutch of clinical trials.

The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that causes strokes.

The series B round equips the team that led BioVex to a $1 billion buyout by Amgen to take another crack at developing a cancer-fighting virus.

After getting off a $102 million series A, Gritstone Oncology has followed up with an impressive $92.7 million second round.

Stemcentrx backer Artis Ventures led the $10 million seed round to equip Excision to start human testing of its CRISPR-enabled attack on latent HIV.

The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.

Destiny's IPO gives it £15.3 million to assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial.

OrbiMed has launched its third Asia-focused biopharma and healthcare fund with more than half a billion dollars’ worth of private equity.

Venture Capital